JP2007530635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530635A5 JP2007530635A5 JP2007505537A JP2007505537A JP2007530635A5 JP 2007530635 A5 JP2007530635 A5 JP 2007530635A5 JP 2007505537 A JP2007505537 A JP 2007505537A JP 2007505537 A JP2007505537 A JP 2007505537A JP 2007530635 A5 JP2007530635 A5 JP 2007530635A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- hydroxy
- represents hydrogen
- halo
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 64
- 239000001257 hydrogen Substances 0.000 claims 64
- 150000002431 hydrogen Chemical class 0.000 claims 48
- 125000005843 halogen group Chemical group 0.000 claims 37
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000003672 ureas Chemical class 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 125000001188 haloalkyl group Chemical group 0.000 claims 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 125000004438 haloalkoxy group Chemical group 0.000 claims 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 7
- -1 cyano, nitro, amino Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical class NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- RKJVTQDJANQBCQ-UHFFFAOYSA-N 1-(2-amino-4,5-dichlorophenyl)-3-[2-chloro-5-(trifluoromethyl)phenyl]urea Chemical compound NC1=CC(Cl)=C(Cl)C=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl RKJVTQDJANQBCQ-UHFFFAOYSA-N 0.000 claims 1
- BNUHODYAAMQTJV-UHFFFAOYSA-N 1-(2-amino-6-hydroxyphenyl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound NC1=CC=CC(O)=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 BNUHODYAAMQTJV-UHFFFAOYSA-N 0.000 claims 1
- ULOBWFQFTPJMGJ-UHFFFAOYSA-N 1-(2-hydroxy-6-nitrophenyl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound OC1=CC=CC([N+]([O-])=O)=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 ULOBWFQFTPJMGJ-UHFFFAOYSA-N 0.000 claims 1
- HNTMOGAMWRYMHA-UHFFFAOYSA-N 1-(3,5-dichloro-4-hydroxyphenyl)-3-(3-phenylphenyl)urea Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1NC(=O)NC1=CC=CC(C=2C=CC=CC=2)=C1 HNTMOGAMWRYMHA-UHFFFAOYSA-N 0.000 claims 1
- TXPYJBVRPJRUQL-UHFFFAOYSA-N 1-(3,5-dichloro-4-hydroxyphenyl)-3-(4-phenylphenyl)urea Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1NC(=O)NC1=CC=C(C=2C=CC=CC=2)C=C1 TXPYJBVRPJRUQL-UHFFFAOYSA-N 0.000 claims 1
- FAWIIPHQRGSJDT-UHFFFAOYSA-N 1-(3,5-dichloro-4-hydroxyphenyl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 FAWIIPHQRGSJDT-UHFFFAOYSA-N 0.000 claims 1
- WQWQRFNJWNSZRT-UHFFFAOYSA-N 1-(3-bromo-5-chloro-2-hydroxyphenyl)-3-[2-chloro-5-(trifluoromethyl)phenyl]urea Chemical compound OC1=C(Br)C=C(Cl)C=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl WQWQRFNJWNSZRT-UHFFFAOYSA-N 0.000 claims 1
- DHTHORLNMVCEAU-UHFFFAOYSA-N 1-(3-chloro-4-hydroxyphenyl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(Cl)C(O)=CC=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 DHTHORLNMVCEAU-UHFFFAOYSA-N 0.000 claims 1
- REACISFIAOQOEW-UHFFFAOYSA-N 1-(3-hydroxy-5-methylphenyl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound CC1=CC(O)=CC(NC(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 REACISFIAOQOEW-UHFFFAOYSA-N 0.000 claims 1
- HDNTXGPZSHXXNF-UHFFFAOYSA-N 1-(4-hydroxy-2-methylphenyl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound CC1=CC(O)=CC=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 HDNTXGPZSHXXNF-UHFFFAOYSA-N 0.000 claims 1
- OSRJFFDHMMTEOE-UHFFFAOYSA-N 1-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxy-4-nitrophenyl)urea Chemical compound OC1=CC=C(Cl)C=C1NC(=O)NC1=CC=C([N+]([O-])=O)C=C1O OSRJFFDHMMTEOE-UHFFFAOYSA-N 0.000 claims 1
- UGBYWTFBYWRHHF-UHFFFAOYSA-N 1-(5-chloro-2-hydroxyphenyl)-3-(4-phenylphenyl)urea Chemical compound OC1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(C=2C=CC=CC=2)C=C1 UGBYWTFBYWRHHF-UHFFFAOYSA-N 0.000 claims 1
- OUDXRNQPVSMGDW-UHFFFAOYSA-N 1-(5-chloro-2-hydroxyphenyl)-3-[2-chloro-5-(trifluoromethyl)phenyl]urea Chemical compound OC1=CC=C(Cl)C=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl OUDXRNQPVSMGDW-UHFFFAOYSA-N 0.000 claims 1
- JYSGFTLBGUTNFL-UHFFFAOYSA-N 1-(5-chloro-2-methoxyphenyl)-3-(2-hydroxy-4-nitrophenyl)urea Chemical compound COC1=CC=C(Cl)C=C1NC(=O)NC1=CC=C([N+]([O-])=O)C=C1O JYSGFTLBGUTNFL-UHFFFAOYSA-N 0.000 claims 1
- HGTNAHXLPRRYOU-UHFFFAOYSA-N 1-(5-chloro-2-methoxyphenyl)-3-[2-chloro-5-(trifluoromethyl)phenyl]urea Chemical compound COC1=CC=C(Cl)C=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl HGTNAHXLPRRYOU-UHFFFAOYSA-N 0.000 claims 1
- PBKRQAUIJPXLKE-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-(3,5-dichloro-2-hydroxyphenyl)urea Chemical compound OC1=C(Cl)C=C(Cl)C=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl PBKRQAUIJPXLKE-UHFFFAOYSA-N 0.000 claims 1
- AHNRQMGGVDYUHK-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-(3,5-dichloro-4-hydroxyphenyl)urea Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl AHNRQMGGVDYUHK-UHFFFAOYSA-N 0.000 claims 1
- UHGHDJAPQFIHPC-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-(3-hydroxy-5-methylphenyl)urea Chemical compound CC1=CC(O)=CC(NC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)=C1 UHGHDJAPQFIHPC-UHFFFAOYSA-N 0.000 claims 1
- DZIWWFOGOSMHGX-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-3-(4-hydroxy-2-methylphenyl)urea Chemical compound CC1=CC(O)=CC=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl DZIWWFOGOSMHGX-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001856 erectile effect Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 206010020765 hypersomnia Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000009863 inflammatory diarrhea Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- UVHPKGYWIYNBJN-UHFFFAOYSA-N n-[4,5-dichloro-2-[[2-chloro-5-(trifluoromethyl)phenyl]carbamoylamino]phenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(Cl)C=C1NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl UVHPKGYWIYNBJN-UHFFFAOYSA-N 0.000 claims 1
- 239000004081 narcotic agent Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- CMUOJBJRZUHRMU-UHFFFAOYSA-N nitrourea Chemical class NC(=O)N[N+]([O-])=O CMUOJBJRZUHRMU-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400498 | 2004-03-29 | ||
| US55769804P | 2004-03-31 | 2004-03-31 | |
| PCT/EP2005/051183 WO2005092843A1 (en) | 2004-03-29 | 2005-03-16 | Novel urea derivatives and their medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007530635A JP2007530635A (ja) | 2007-11-01 |
| JP2007530635A5 true JP2007530635A5 (https=) | 2008-04-24 |
Family
ID=37818161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505537A Abandoned JP2007530635A (ja) | 2004-03-29 | 2005-03-16 | 新規尿素誘導体群およびそれらの利用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070142450A1 (https=) |
| EP (1) | EP1732883A1 (https=) |
| JP (1) | JP2007530635A (https=) |
| CN (1) | CN1926098A (https=) |
| AU (1) | AU2005225559A1 (https=) |
| BR (1) | BRPI0507296A (https=) |
| CA (1) | CA2561639A1 (https=) |
| RU (1) | RU2006131454A (https=) |
| WO (1) | WO2005092843A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006089871A2 (en) * | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
| US20100234349A1 (en) * | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| WO2010130063A1 (zh) * | 2009-05-12 | 2010-11-18 | Han Mei | 具有促进干細胞增殖作用的小分子化合物及其用途 |
| EP2611437B1 (en) * | 2010-09-02 | 2017-03-29 | Kyoto University | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
| SG192078A1 (en) | 2011-02-03 | 2013-08-30 | Lupin Ltd | Pyrrole derivatives used as modulators of alpha7 nachr |
| ES2594409T3 (es) | 2011-02-23 | 2016-12-20 | Lupin Limited | Derivados de heteroarilo como moduladores del nAChR á7 |
| WO2012131576A1 (en) | 2011-03-31 | 2012-10-04 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
| KR20140027939A (ko) | 2011-06-30 | 2014-03-07 | 도레이 카부시키가이샤 | 지양제 |
| EP2729455B1 (en) | 2011-07-05 | 2016-09-14 | Lupin Limited | Biaryl derivatives as nachr modulators |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| CN103172543B (zh) * | 2011-12-21 | 2016-02-10 | 中国科学院上海药物研究所 | 一种脲类化合物、制备方法及其用途 |
| NZ629453A (en) | 2012-03-06 | 2016-04-29 | Lupin Ltd | Thiazole derivatives as alpha 7 nachr modulators |
| US20150299178A1 (en) | 2012-11-12 | 2015-10-22 | Lupin Limited | Thiazole Derivatives as Alpha 7 NACHR Modulators |
| US9617211B2 (en) | 2013-01-16 | 2017-04-11 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| US9617210B2 (en) | 2013-03-13 | 2017-04-11 | Lupin Limited | Pyrrole derivatives as alpha 7 NACHR modulators |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| AU2014282886A1 (en) | 2013-06-17 | 2015-12-17 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3237479A1 (de) * | 1982-10-09 | 1984-04-12 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von substituierten tetrahydropyrimidinonderivaten |
| DK41193D0 (da) * | 1993-04-07 | 1993-04-07 | Neurosearch As | Ionkanalaabnere |
| KR20030097618A (ko) * | 1993-05-27 | 2003-12-31 | 캠브리지 뉴로사이언스, 인코포레이티드 | 치료용 치환 구아니딘류 |
| EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| AU2962297A (en) * | 1996-05-24 | 1998-01-05 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
| JP3887769B2 (ja) * | 1997-12-22 | 2007-02-28 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害 |
| WO2000001349A2 (en) * | 1998-07-01 | 2000-01-13 | The Trustees Of The University Of Pennsylvania | Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same |
| JP2004523543A (ja) * | 2001-02-15 | 2004-08-05 | ニューロサーチ、アクティーゼルスカブ | 神経栄養活性を有する化合物とドパミン活性を増加させる化合物の組み合わせ作用によるパーキンソン病の治療法 |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
-
2005
- 2005-03-16 WO PCT/EP2005/051183 patent/WO2005092843A1/en not_active Ceased
- 2005-03-16 JP JP2007505537A patent/JP2007530635A/ja not_active Abandoned
- 2005-03-16 RU RU2006131454/04A patent/RU2006131454A/ru not_active Application Discontinuation
- 2005-03-16 US US10/590,104 patent/US20070142450A1/en not_active Abandoned
- 2005-03-16 AU AU2005225559A patent/AU2005225559A1/en not_active Abandoned
- 2005-03-16 CN CNA200580006364XA patent/CN1926098A/zh active Pending
- 2005-03-16 EP EP05717055A patent/EP1732883A1/en not_active Withdrawn
- 2005-03-16 BR BRPI0507296-4A patent/BRPI0507296A/pt not_active Application Discontinuation
- 2005-03-16 CA CA002561639A patent/CA2561639A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530635A5 (https=) | ||
| RU2006131454A (ru) | Новые производные мочевины и их медицинское применение | |
| JP2006508109A5 (https=) | ||
| JP2009538870A5 (https=) | ||
| JP2009538869A5 (https=) | ||
| JP2009538867A5 (https=) | ||
| DE602004010299T2 (de) | Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen | |
| CN100432075C (zh) | 作为烟碱样乙酰胆碱受体配体的二氮杂双环芳基衍生物 | |
| CA2566155C (en) | 1-aza-bicyclo[3.3.1]nonanes | |
| JP2009537599A5 (https=) | ||
| JP2009538866A5 (https=) | ||
| JP2008530171A5 (https=) | ||
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| NZ551800A (en) | 3-(Heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha7-nAChR ligands for the treatment of CNS diseases | |
| CA2409644A1 (en) | Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands | |
| JP2010535738A5 (https=) | ||
| JP2008533087A5 (https=) | ||
| JP2007520525A5 (https=) | ||
| CA2632893C (en) | (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders | |
| JP2009526776A5 (https=) | ||
| JP2006503062A5 (https=) | ||
| JP2009526024A5 (https=) | ||
| JP2005530814A5 (https=) | ||
| JP2009537598A5 (https=) | ||
| JP2005524712A5 (https=) |